Minimal nephrotoxicity with cephalosporin-aminoglycoside combinations in patients with neoplastic disease
Open Access
- 1 April 1982
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 21 (4) , 592-594
- https://doi.org/10.1128/aac.21.4.592
Abstract
Patients with cancer and suspected sepsis were treated in a prospective, randomized trial with one of four cephalosporin-aminoglycoside combinations: cephalothin and tobramycin; cephalothin and gentamicin; cefamandole and tobramycin; or cefamandole and gentamicin. Carbenicillin was added if the absolute granulocyte count was less than 1,000/mm3. Of 199 patients receiving 20 to more doses of an aminoglycoside and having serial determination of serum creatinines, nephrotoxicity developed in seven (3.5%) given any of the four combinations. There were no significant differences between patients receiving either cephalosporin or either aminoglycoside. Nephrotoxicity developed less frequently among children (2 or 125; 1.6%) than adults (5 of 74; 6.8%).This publication has 4 references indexed in Scilit:
- Double-Blind Comparison of the Nephrotoxicity and Auditory Toxicity of Gentamicin and TobramycinNew England Journal of Medicine, 1980
- Improved prognosis for granulocytopenic patients with gram-negative bacteremiaThe American Journal of Medicine, 1980
- CEPHALOTHIN PLUS AN AMINOGLYCOSIDE IS MORE NEPHROTOXIC THAN METHICILLIN PLUS AN AMINOGLYCOSIDEThe Lancet, 1978
- Bacteremia and fungemia complicating neoplastic diseaseThe American Journal of Medicine, 1977